Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ponvory
Pharma
Cycle's 2nd hostile takeover bid in 5 months rejected by Vanda
For the second time in five months, Vanda Pharmaceuticals has rejected an $8-per-share takeover bid from Cycle Pharmaceuticals of England.
Kevin Dunleavy
Oct 14, 2024 3:18pm
J&J unloads certain Ponvory rights to Vanda for $100M
Dec 7, 2023 11:57pm
J&J's Ponvory late to MS market, but docs still see potential
Aug 10, 2021 11:00am
Even during pandemic, FDA approvals remain on a rapid pace
Jul 6, 2021 11:27am
J&J offers guide helping Black Americans live well with MS
Apr 19, 2021 8:40am
J&J elbows into crowded MS market with FDA nod for Ponvory
Mar 19, 2021 10:09am
